Protocol Ledger

NCT07226752 · Phase III · ACTIVE NOT RECRUITING

A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China

Interventional Phase III clinical trial protocol NCT07226752 sponsored by Genmab in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-10-08 Enrollment: 72 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT07226752
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)72 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07226752
Protocol FieldVerified Registry Value
NCT IdentifierNCT07226752
Consolidated Lead SponsorGenmab
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment72 participants (ACTUAL)
Registered Start Date2022-10-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI